近日，苏州迪凯尔医疗科技有限公司（下称“迪凯尔”）宣布完成近亿元人民币的C轮融资。本轮融资由恒旭资本领投，现有股东汇鼎资本跟投，点石资本担任独家财务顾问。本轮融资所筹资金将用于扩大团队规模，推进市场渠道建设、拓展产品管线等。
迪凯尔成立于2010年，是一家专注于手术导航机器人研发和产业化的高科技医疗器械公司。公司现阶段已打造围绕口腔种植手术的多款核心产品，未来将基于导航机器人概念进一步拓展至其他科室应用场景。
我国口腔行业供给端目前还存在诸多不足，对诊疗流程标准化以及手术安全性、有效性等结果均有影响。公立医院及私立诊所亟需提高营运效率，数字化和智能化成为发展方向，催生计算机辅助导航技术的普及，在种植牙赛道尤为明显。动态可视导航系统在微创、安全性上大大提升病人体验，并大大提升基础医生效率，且实现种植牙手术适应症全覆盖，满足患者多元化诊疗需求。目前，迪凯尔已经建立起平均从业经验15年以上的专业口腔团队，从口腔种植手术系统研发起步，并扩展至于其他科室。公司核心产品“易植美”作为国内唯一获批三类注册证的口腔种植手术实时导航系统，已进入北大、武大、华西等顶级口腔医院，多年来实现销量稳定高增长。
截止目前，迪凯尔已累计申请发明专利40余项，公司一方面通过手术教学系统和正畸业务进一步巩固口腔领域龙头地位；另一方面也积极推进手术导航系统在其他科室的应用，力争实现多科室全面布局，形成协同效应。
迪凯尔总经理兼董事长陈云表示：“我们非常感谢恒旭资本和汇鼎资本对于本轮融资的大力支持。迪凯尔为种植患者提供便捷、安全的手术选择。我们已上市的口腔种植手术导航系统及口腔技能训练及实时评估系统均达到国际领先水平，为患者提供更高的手术精准度与定制化服务。未来，迪凯尔将在现有牙科产品不断迭代的基础上，充分发挥手术机器人平台的通用性，致力于成为一家综合性平台型公司。
恒旭资本董事长陆永涛表示：“我国种植牙市场正处在高速发展期，在老龄化冲击下，种植需求将进一步加速释放。目前，后疫情时代的牙科下半场竞争已经集中在数字化领域，我国市场对数字设备的需求大幅增长。迪凯尔作为最早布局牙科数字化领域的企业之一，目前已成功在产品研发和市场推广两端建立高壁垒，形成核心竞争力。迪凯尔发力攻关的手术机器人是恒旭在数字化医疗领域关注的重点赛道，我们期待团队的持续创新能力，相信迪凯尔能成为一家有国际化影响力的机器人公司。
汇鼎资本管理合伙人何欣博士表示：“手术数字化是发展趋势，手术导航系统提高了医生的诊疗精确度，降低医生学习曲线；同时让手术更微创，术中反馈更实时，利好患者快速实现术后康复。迪凯尔的产品经历了研发期、市场导入期，已与牙科种植全流程紧密嵌合；让临床医生愿意用、用得好。这是汇鼎资本第二次与迪凯尔团队合作，我们看好迪凯尔团队持续商业化能力，也对公司基于底层导航技术的产品拓展充满信心，期待越来越多的牙科患者能从公司产品中获益。”
[:en]We have been working intensively with DAS Capital to identify, select and approach potential financial/strategic investors for our breakthrough technology. We are deeply impressed by the team’s professionalism, and we believe DAS Capital will become a national-leading Financial advisor in the industry.
——Yun Chen, Managing Director at DCARER
@DAS Capital’s client, @DCARER recently finished its RMB 100 million Series C funding round. The investors are composed of @SAIC Hengxu Capital, a fund of funds under SAIC Motor Corporation Limited (SHA: 600104), and current shareholder, Hyfinity Investments. The funds raised will be used to develop current product pipelines, explore new customers, and expand the research and sales team.
Founded in 2010, DCARER is a high-tech medical device company focusing on the R&D and industrialization of surgical navigation robots. At this stage, DCARER’s core products are mainly used during oral implant surgery. The company will further extend its product pipelines to application scenarios in other departments including cosmetology, orthopedics, etc.
China’s oral industry still faces a lot of shortcomings on the supply side, which affects the standardization of the diagnosis/treatment process and surgery’s safety and effectiveness. The demand for improving surgery efficiency from public and private hospitals generates large unmet needs of digitalization. As a result, the computer-aided navigation technology will be widely used to support the operation, especially in the dental implant segment. While the patients benefit from minimal invasiveness and safe surgeries, dentists improve their efficiency and could achieve full coverage of indications to tailor services with the help from the latest technology, the dynamic visual navigation system.
DCARER has established a professional execution team with an average experience of more than 15 years. The company’s competitive product YiZhiMei (“易植美”), currently the only NMPA approved domestic real-time navigation system (level 3) for dental implant surgery, has already established reputation in the high-end market. DECARER has long-term cooperative relationships with top dental hospitals, such as PKU Hospital of Stomatology(“北京大学口腔医院”), and West China Hospital of Stomatology Sichuan University(“四川大学华西口腔医院”). YiZhiMei has achieved high growth in sales for many years since its launch.
Up to now, DCARER has applied for more than 40 invention patents. Strategically the company will further consolidate its leading position in the oral industry through its surgical teaching system and orthodontic robots; on the other hand, it aims to build a comprehensive product layout in multiple departments to benefit from cost synergies.
Yun Chen, Chairman of DCARER, said: ‘We appreciate Hengxu Capital and Hyfinity Investments for their strong support in this round of financing. DCARER is dedicated to providing convenient and minimally invasive surgery options for Chinese patients. Our dental surgical navigation system has reached the leading level worldwide with highly accurate customized services. In the future, we will continuously upgrade our dental robots, and we are committed to becoming a comprehensive surgical platform.’
Yongtao Lu, Chairman at SAIC Hengxu Capital, said: ‘China’s dental implant market has developed rapidly in recent years, with the demand being further accelerated under the impact of growing aging population. Right now, the competition is concentrated on digital healthcare. As an industry pioneer, DCARER has established its wide moat and makes it hard for competitors to catch up. We think that robots will be the key driver for future market development and we strongly believe that DCARER will become a global leading company in this industry.’
Dr. Xin He, Managing Partner of Hyfinity Investments, said: ‘The surgical navigation system improves surgery accuracy and reduces doctor’s learning curve. At the same time, it makes the operation more minimally invasive, the intraoperative feedback more real-time and the postoperative rehabilitation process more quickly. DCARER products are suitable during dental implant surgery, thus increases dentist’s willingness and proficiency. This is the second time that we choose to co-operate with DCARER. We are optimistic about the company’s continuous commercialization capabilities. We look forward to witnessing more and more dental patients benefiting from the company’s products.’
